Otamixaban Is Promising New Treatment For Patients With Acute Coronary Syndromes (SEPIA-ACS1 TIMI 42 Study)

An Article published Online First and in an upcoming edition of The Lancet shows that otamixaban is a promising new agent for patients with acute coronary syndromes (heart attacks or sudden worsening of angina). The Article, by Dr Marc S Sabatine, TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, and colleagues, is being presented at the European Society of Cardiology meeting, Barcelona.